Roivant reports Q2 net loss $331M; announces $7.1B Telavant sale to Roche

Roivant Sciences Ltd.

2023-Q2 EPS reported -$0.78 revenue$58,725,000

Net loss $331.1M ($0.40/share) vs $315.9M prior year; revenue $37.1M up from $12.5M.
Sold Telavant to Roche for $7.1B upfront + $150M milestone; Roivant net proceeds ~$5.2B.
VTAMA net product revenue $18.4M in quarter; over 250k prescriptions since launch.
Pro forma cash ~$7.0B after Telavant and Immunovant offerings; R&D spend $132M.
IMVT-1402 Phase 1 data show dose-dependent IgG reduction with no significant albumin/LDL-C changes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported financial results for the second quarter ended September 30, 2023.

Period: the second quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-052718

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.